Program
Levetiracetam
Also written as “Levetiracetam (Keppra)”, “levetiracetam” and “Levetiracetam 250 mg”.
Its studies are mostly in Epilepsy · Epilepsies, Partial · Seizures · Cognitive Dysfunction · Epilepsy, Generalized, led by 8 companies.
Drug pageLevetiracetam: every studyMany companies study it; this page follows only the 72 they lead. All 204 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCBits history only | 570 open or running | phase 4since Sep 8, 2005 | Mar 3, 2005 | none ahead |
| Hikma Pharmaceuticalsits history only | 40 open or running | no phasesince Jan 15, 2009 | Jan 15, 2009 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Feb 20, 2009 | Feb 20, 2009 | none ahead |
| AgeneBioits history only | 20 open or running | phase 3since Mar 28, 2018 | Mar 28, 2018 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since May 26, 2010 | May 26, 2010 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Jul 6, 2011 | Jul 6, 2011 | none ahead |
| Desitin Arzneimittelits history only | 10 open or running | phase 1since Dec 1, 2025 | Dec 1, 2025 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Jul 24, 2009 | Jul 24, 2009 | none ahead |
Also a collaborator on its studies: PRA Health Sciences and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Sep 8, 2005.
- Jul 6, 2011Ache Laboratorios Farmaceuticos’ first study: phase 3 study in EpilepsyNew to Ache Laboratorios FarmaceuticosAche Laboratorios Farmaceuticos · NCT01392768 · 126 enrolled
- Jul 12, 2011Phase 1 study in Healthy VolunteersUCB · NCT01394224 · 25 enrolled · United Kingdom
- Jul 13, 2011Phase 3 study in EpilepsyUCB · NCT01398956 · 44 enrolled · Japan
- Jul 29, 2011Phase 2 study in EpilepsyUCB · NCT01407523 · 16 enrolled · Japan
- Dec 9, 20112 phase 4 studiesUCB · NCT01491113, NCT01498822
- Jan 5, 2012Phase 3 study in EpilepsyUCB · NCT01506882 · 71 enrolled · Japan
- Jun 11, 20122 phase 1 studies in Human VolunteersUCB · NCT01618903, NCT01618877
- Nov 7, 2012Phase 1 study in Healthy VolunteersUCB · NCT01725009 · 32 enrolled · Japan
- Sep 26, 2013Phase 3 study in EpilepsyUCB · NCT01954121 · 436 enrolled · China
- Nov 6, 2015Phase 1 study in Healthy VolunteersUCB · NCT02602860 · 13 enrolled · United States
- Nov 8, 2017Phase 3 study in SeizuresUCB · NCT03340064 · 38 enrolled · Japan
- Mar 28, 2018AgeneBio’s first study: phase 3 study in Cognitive DysfunctionNew to AgeneBioAgeneBio · NCT03486938 · 164 enrolled · United States, Canada
- Aug 3, 2023Phase 2 study in Cognitive DysfunctionAgeneBio · NCT05986721 · United States
- Dec 1, 2025Desitin Arzneimittel’s first study: phase 1 study in Pharmacokinetic AnalysisNew to Desitin ArzneimittelDesitin Arzneimittel · NCT07393022 · 20 enrolled · Canada
TargetBeta
“Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker”ChEMBL 37, by rule
Studies
The newest 60 of 72 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07393022Pharmacokinetic Analysis · Canada | 1 | Completed | Desitin Arzneimittel | Jan 5, 2026 | 20 |
| NCT05986721Cognitive Dysfunction · United States | 2 | Withdrawn | AgeneBio | Jul 2028 | 0 |
| NCT03486938Cognitive Dysfunction · United States, Canada | 3 | Completed | AgeneBio | Nov 2, 2022 | 164 |
| NCT03340064Seizures · Japan | 3 | Completed | UCB | Jun 1, 2021 | 38 |
| NCT02602860Healthy Volunteers · United States | 1 | Completed | UCB | Sep 2017 | 13 |
| NCT01954121Epilepsy · China | 3 | Completed | UCB | Sep 2015 | 436 |
| NCT01725009Healthy Volunteers · Japan | 1 | Completed | UCB | Dec 2012 | 32 |
| NCT01618903Human Volunteers · China | 1 | Completed | UCB | Jul 2012 | 24 |
| NCT01618877Human Volunteers · China | 1 | Completed | UCB | Jul 2012 | 24 |
| NCT01506882Epilepsy · Japan | 3 | Completed | UCB | Oct 2013 | 71 |
| NCT01498822Epilepsy · Korea, Republic of | 4 | Completed | UCB | Jul 2014 | 353 |
| NCT01491113Healthy Subjects · Japan | 4 | Completed | UCB | Nov 2012 | 30 |
| NCT01407523Epilepsy · Japan | 2 | Completed | UCB | Feb 2012 | 16 |
| NCT01398956Epilepsy · Japan | 3 | Completed | UCB | Apr 2016 | 44 |
| NCT01394224Healthy Volunteers · United Kingdom | 1 | Completed | UCB | Sep 2011 | 25 |
| NCT01392768Epilepsy | 3 | Completed | Ache Laboratorios Farmaceuticos | Jul 2015 | 126 |
| NCT01375374Epilepsies, Partial · Austria, Germany, Spain | 3 | Terminated | UCB | Mar 2013 | 11 |
| NCT01292837Epilepsy · Japan | 3 | Completed | UCB | Jun 2013 | 13 |
| NCT01229735Epilepsy · Korea, Republic of | 4 | Completed | UCB | May 2015 | 343 |
| NCT01228747Epilepsy · China, Japan | 3 | Completed | UCB | Apr 2014 | 361 |
| NCT01132352Healthy · United States | 1 | Completed | Dr. Reddy's Laboratories | Oct 2003 | 24 |
| NCT01131897Healthy · United States | 1 | Completed | Dr. Reddy's Laboratories | Sep 2003 | 24 |
| NCT01063764Epilepsy · Japan | 3 | Completed | UCB | Apr 2011 | 73 |
| NCT00985348Healthy · United Kingdom | 1 | Completed | UCB | Oct 2009 | 26 |
| NCT00961441Epilepsy · United States | 2 | Completed | UCB | Mar 2010 | 25 |
| NCT00946751Seizures | 1 | Completed | Novartis | Mar 2004 | 20 |
| NCT00859521Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 2007 | 30 |
| NCT00859430Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 2007 | 22 |
| NCT00849862Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Nov 2005 | 22 |
| NCT00849485Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Nov 2005 | 22 |
| NCT00826787Seizures · United States | – | Completed | Hikma Pharmaceuticals | Aug 2005 | 29 |
| NCT00827320Seizures · United States | – | Completed | Hikma Pharmaceuticals | Jun 2007 | 26 |
| NCT00826865Seizures · United States | – | Completed | Hikma Pharmaceuticals | Aug 2005 | 27 |
| NCT00826722Seizures · United States | – | Completed | Hikma Pharmaceuticals | Jun 2007 | 30 |
| NCT00631150Epilepsy | 4 | Completed | UCB | Jul 2004 | 35 |
| NCT00630968Epilepsy | 4 | Completed | UCB | Feb 2004 | 1,541 |
| NCT00630630Epilepsy | 4 | Completed | UCB | Nov 2003 | 3 |
| NCT00630357Epilepsy | 4 | Completed | UCB | Jul 2004 | 14 |
| NCT00643500Epilepsies, Partial | 4 | Completed | UCB | May 2003 | 342 |
| NCT00615615Epilepsy | 3 | Completed | UCB | Mar 2003 | 216 |
| NCT00610454Epilepsy | 2 | Completed | UCB | Aug 2004 | 25 |
| NCT00612859Anxiety Disorders | 2 | Completed | UCB | Jun 2004 | 217 |
| NCT00600509Epilepsy | 2 | Completed | UCB | Jul 2003 | 216 |
| NCT00545012Seizures | 2 | Completed | UCB | May 2003 | 4 |
| NCT00544050Epilepsy | 2 | Completed | UCB | May 2003 | 13 |
| NCT00535392Epilepsy · United States, Belgium, France and more | 2 | Completed | UCB | Feb 2010 | 33 |
| NCT00505934Epilepsy · United States, Belgium, France and more | 2 | Completed | UCB | Mar 2010 | 19 |
| NCT00419393Epilepsy · United States, Mexico, Poland and more | 3 | Completed | UCB | Mar 2010 | 190 |
| NCT00419094Epilepsy · United States, Mexico, Poland and more | 3 | Completed | UCB | Sep 2009 | 228 |
| NCT00367432Epilepsy · Japan | 3 | Completed | UCB | Dec 2010 | 398 |
| NCT00368069Epilepsy · Brazil, Finland, India and more | 3 | Completed | UCB | May 2007 | 158 |
| NCT00291655Epilepsy · Belgium, Bulgaria, Finland and more | 3 | Completed | UCB | Apr 2008 | 130 |
| NCT00280696Epilepsies, Partial · Japan | 3 | Completed | UCB | Nov 2007 | 352 |
| NCT00245713Epilepsies, Partial | 4 | Completed | UCB | Nov 2004 | 40 |
| NCT00175955Dyskinesia, Drug-Induced · Belgium, Bulgaria | 2 | Completed | UCB | Dec 2005 | 70 |
| NCT00175903Epilepsy · Australia, Austria, Belgium and more | 3 | Completed | UCB | Oct 2007 | 1,701 |
| NCT00175890Epilepsies, Partial · United States, Argentina, Belgium and more | 3 | Completed | UCB | Jan 2007 | 116 |
| NCT00160654Epilepsies, Partial · Hong Kong, Malaysia, Philippines and more | 4 | Completed | UCB | Dec 12, 2006 | 251 |
| NCT00160628Epilepsies, Partial | 3 | Completed | UCB | Oct 2004 | 100 |
| NCT00160615Epilepsies, Partial | 3 | Completed | UCB | Jan 17, 2007 | 154 |
How it is read
Names in the registry
- “Levetiracetam”, 52 entries
- “Levetiracetam (Keppra)”, 4 entries
- “levetiracetam”, 3 entries
- “Levetiracetam 250 mg”, 3 entries
- “Levetiracetam 500 mg”, 3 entries
Conditions, from the studies’ own filings
- Epilepsy, 26 studies
- Epilepsies, Partial, 13 studies
- Seizures, 8 studies
- Cognitive Dysfunction, 2 studies
- Epilepsy, Generalized, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.